Xpovio (selinexor), a treatment for advanced multiple myeloma, may soon be available in Israel and the Palestinian Authority through Promedico, under an exclusive…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Janssen‘s Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone continues to lead to strong and durable responses, and…
KP1237, an experimental therapy by Kleo Pharmaceutical that harnesses the body’s natural antibodies to fight cancers, will soon enter clinical testing for…
A clinical trial is soon to begin testing Precision BioSciences‘s new CAR T-cell therapy candidate, PBCAR269A, in people with relapsed or refractory multiple myeloma.
Janssen has asked the U.S. Food and Drug Administration (FDA) to allow Darzalex…
Preventive treatment with the antibiotic levofloxacin can lower the incidence of fever and death in people newly diagnosed with multiple myeloma, results from a…
